Pay in 4 interest-free payments of $5.97 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
The solution might look fine after shaking
MASH resolution without worsening of fibrosis: 2.4 mg dose: 47% of participants (vs 14% placebo) 4.8 mg dose: 62% of participants (vs 14% placebo) 6.0 mg dose: 43% of participants (vs 14% placebo) Liver fat reduction of at least 30%: 2.4 mg dose: 63% of participants 4.8 mg dose: 67% of participants 6.0 mg dose: 57% of participants Placebo: 14% of participants Fibrosis improvement by at least one stage: Survodutide groups: 34-36% Placebo: 22% The percentage change from baseline in liver fat content after 48 weeks was a staggering 62% reduction in the 6.0 mg group, compared to just 5.7% in the placebo group
It is typically preferred when a product is used over several weeks
Fang Y, Su Y, Xu J, et al
US$ 25.32
US$ 20.25
US$ 28.55
US$ 27.35
.webp)
US$ 24.69
US$ 24.75
US$ 27.21
